Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Subhashini Gowda

Clinical Cardiac Electrophysiology Somerset, NJ Medical Doctor

NPI 1225058423 CMS profile 10164

75 Veronica Ave, Suite 101, Somerset, NJ 08873

Open in the dashboard

General payments

$59,545

374 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$30,925 paid to institutions, not to them · program years 2019–2021

Through program year 2025, Subhashini Gowda of Somerset, NJ is reported in the CMS Open Payments database as having received $59,545 across 374 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $30,925 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 80th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,539 59
2024 General $14,409 90
2023 General $2,632 59
2022 General $3,127 54
2021 General $1,965 31
2020 General $5,812 20
2019 General $26,062 61

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Subhashini Gowda
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Subhashini Gowda were reported at $5,539. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Subhashini Gowda Clinical Cardiac Electrophysiology median Middle half National median
2019 $26,062 $2,361 $585–$8,260 $163
2020 $5,812 $993 $247–$4,351 $114
2021 $1,965 $1,185 $326–$4,739 $132
2022 $3,127 $2,073 $554–$6,789 $149
2023 $2,632 $2,568 $759–$8,159 $160
2024 $14,409 $2,557 $703–$7,403 $164
2025 $5,539 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $33,706 160 payments
  2. Janssen Pharmaceuticals, Inc $9,191 34 payments
  3. Pfizer Inc. $5,697 28 payments
  4. Boston Scientific Corporation $3,371 22 payments
  5. Medtronic, Inc. $2,163 25 payments
  6. E.R. Squibb & Sons, L.L.C. $1,823 47 payments
  7. Medtronic Vascular, Inc. $1,514 8 payments
  8. CVRx, Inc. $338 3 payments
  9. Philips Electronics North America Corporation $248 6 payments
  10. Novartis Pharmaceuticals Corporation $199 11 payments
  11. Other $1,293 30 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $17,048 14 payments
  2. Food and Beverage $15,149 317 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,050 10 payments
  4. Travel and Lodging $7,623 31 payments
  5. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $4,675 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $9,191 34 payments
  2. AMPLATZER AMULET Vascular $7,950 9 payments
  3. Ensite Cardiac Mapping System $7,658 4 payments
  4. ELIQUIS Cardiovascular;Metabolic Disease $5,697 28 payments
  5. AMPLATZER AMULET Structural Heart $2,866 19 payments
  6. Anthem CRT Pacemaker $2,461 5 payments
  7. General - Therapies $2,341 5 payments
  8. Endurity Pacemaker $1,926 4 payments
  9. AVEIR $1,583 11 payments
  10. ELIQUIS Cardiovascular $1,561 31 payments
  11. Other $13,077 223 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 56 drugs

Part D claims

5,915

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$1,294,699

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

26.5%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 560 $679,208
Xarelto Rivaroxaban Brand 231 $286,166
Entresto Sacubitril/Valsartan Brand 71 $95,608
Multaq Dronedarone Hcl Brand 72 $93,813
Farxiga Dapagliflozin Propanediol Brand 13 $17,620
Dofetilide Generic 80 $17,432
Metoprolol Succinate Generic 1,027 $16,763
Brilinta Ticagrelor Brand 13 $14,496
Flecainide Acetate Generic 168 $9,621
Amiodarone Hcl Generic 116 $6,077

The 10 drugs with the highest cost, of 56 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$464,768

Of which drugs: $379

Medicare patients

1,206

Average age 78

Services billed

7,160

599 women, 607 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 55%
Atrial fibrillation 53%
Arthritis 52%
Diabetes 41%
Heart failure 36%
Chronic kidney disease 31%
COPD 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, regadenoson, 0.1 mg J2785 Office 13 52 $365

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $170
$170 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $107
$107 231 —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $75
$75 71 —
ELIQUIS
  • PFIZER INC. $35
  • E.R. Squibb & Sons, L.L.C. $24
$59 560 —
PAXLOVID
  • PFIZER INC. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

374 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record